CCMDS/AML Preliminary Agenda 2024
Friday September 20, 2024
Fairmont Palliser Hotel, Calgary, AB
| 7:30 am – 8:30 am | Breakfast |
| 8:30 am – 8:35 am | CCMDS/AML Welcome – Dr. Michelle Geddes |
| 8:35 am – 12:20 pm | Morning Sessions and Introductions |
| 8:35 am – 9:00 am | Prognostication – Molecular Testing and What is Next – Genomes and Transcriptomes and Clinical Relevance – Speaker TBD |
| 9:00 am – 9:25 am | Machine Learning and Insights in Management of Clinical Cases – Speaker TBD |
| 9:25 am – 9:50 am | What is New in Clinical Trials for Lower Risk MDS? – Dr. Valeria Santini |
| 9:50 am – 10:15 am | Optical Genome Mapping and Role in AML and MDS – With Cases – Dr. Adam Smith |
| 10:15 am – 10:30 am | Question Period – Dr. V. Santini, Dr. A. Smith |
| 10:30 am – 10:50 am | Refreshment Break |
| 10:50 am – 11:15 am | Finding the 5q- Gene – Dr. Celine Moison |
| 11:15 am – 11:40 am | CAN MDS Platform and Research Initiatives – Dr. Brett Houston |
| 11:40 am – 12:05 pm | MDS Registry Update and Initiatives – Dr. Rena Buckstein |
| 12:05 pm – 12:20 pm | Question Period – Dr. R. Buckstein, Dr. B. Houston, Dr. C. Moison |
| 12:20 pm – 1:20 pm | Lunch |
| 1:20 pm – 5:15 pm | Afternoon Sessions: Introductions |
| 1:25 pm – 1:30 pm | Introduction to the Carolyne Delage Investigator Award |
| 1:30 pm – 1:35 pm | Carolyne Delage Young Investigators Award – Presented by Dr. Brian Leber |
| 1:35 pm – 2:00 pm | Epigenetics and Response to Thearpy with HMAs – Dr. Aly Karsan |
| 2:00 pm – 2:25 pm | Impact of IPSS-M in Treatment Decisions and Which Lower Risk Patients Should We Treat Aggressively – Speaker TBD |
| 2:25 pm – 2:50 pm | Fitness for Treatment Decisions in MDS and AML – Dr. Rena Buckstein |
| 2:50 pm – 3:05 pm | Question Period – Dr. R. Buckstein, Dr. A. Karsan |
| 3:05 pm – 3:25 pm | Refreshment Break |
| 3:25 pm – 3:50 pm | Anemia Pathophysiology in MDS – Dr. Valeria Santini |
| 3:50 pm – 4:15 pm | Updates on Clinical Trials Recently Released in MDS: Verona, Imetelstat – Dr. Mikkael Sekeres |
| 4:15 pm – 4:30 pm | Clearpath Update – Dr. Heather Leitch |
| 4:30 pm – 4:45 pm | Question period – Dr. V. Santini, Dr. M. Sekeres, Dr. H. Leitch |
| 4:45 pm – 5:15 pm | Panel Discussion: 3 Cases (5 Minute Each and Discussion)
Panelists: Dr. V. Santini, Dr. M. Sekeres |
| 5:15 pm – 5:20 pm | Closing Remarks |
| 5:20 pm – 7:20 pm | CCMDS AML Welcome Reception |
Saturday September 21, 2024
Fairmont Palliser Hotel, Calgary, AB
| 7:30 am – 8:30 am | Breakfast |
| 8:30 am – 8:35 am | Morning Welcome |
| 8:35 am – 11:50 am | Morning Sessions and Introductions |
| 8:35 am – 9:00 am | Biologic Markers of Response and Resistance to Azacitine and Venetoclax for Newly Diagnosed AML – Dr. Keith Pratz |
| 9:00 am – 9:25 am | FLT-3 Biology and Optimal Role of FLT3 Inhibitors in AML – Dr. Alexander Perl |
| 9:25 am – 9:50 am | Use of Novel Agents in AML in the Canadian Context – Current and Coming Agents – Dr. Brian Leber, Dr. Andre Schuh |
| 9:50 am – 10:05 am | Question Period – Dr. K. Pratz, Dr. A. Perl, Dr. B. Leber, Dr. A. Schuh |
| 10:05 am – 10:20 am | Refreshment Break |
| 10:20 am – 10:45 am | Application of MRD Monitoring in Clinical Practice – Dr. Michael Heuser |
| 10:45 am – 11:10 am | MRD-Driven Therapy of AML – Speaker TBD |
| 11:10 am – 11:35 am | Canadian Perspective on MRD Use and Research Projects/Results – Dr. Steven Chan |
| 11:35 am – 11:50 am | Question Period – Dr. S. Chan, Dr. M. Heuser |
| 11:50 am – 12:50 pm | Lunch – Meet the Experts |
| 12:50 pm – 5:05 pm | Afternoon Sessions and Introductions |
| 12:50 pm – 12:55 pm | Introduction to the Stephen Couban Keynote Lecture |
| 12:55 pm – 1:40 pm | Stephen Couban Keynote Lecture: The Devil p53 in AML and MDS – Dr. David Sallman |
| 1:40 pm – 1:50 pm | Question Period |
| 1:50 pm – 2:05 pm | Refreshment Break |
| 2:05 pm – 2:30 pm | Genetic Classification of AML – The Vancouver Experience, Data on RNA Seq – Dr. Ryan Stubbins |
| 2:30 pm – 2:55 pm | Future Role for MicroRNA in AML Disease Classification – Dr. Florian Kuchenbauer |
| 2:55 pm – 3:20 pm | Relapsed/Refractory AML for Fit and Unfit AML – What Now and What is Coming, Including Ven/aza Failures – Dr. Michael Heuser |
| 3:20 pm – 3:35 pm | Question Period – Dr. R. Stubbins, Dr. F. Kuchenbauer, Dr. M. Heuser |
| 3:35 pm – 3:50 pm | Refreshment Break |
| 3:50 pm – 4:00 pm | Canadian AML Registry – Dr. Kristjan Paulson |
| 4:00 pm – 4:10 pm | CTTG Basket Study Update – Dr. Lynn Savoie |
| 4:10 pm – 4:35 pm | DDX4 Mutation Role in Leukemia Pathogenesis and Role of Familial Testing – Dr. Lucy Godley |
| 4:35 pm – 5:00 pm | Panel Discussion: 3 cases (5 min each and discussion) Panelists: Dr. L. Godley, Dr. J. Othman, Dr. S. Chan, Dr. D. Sallman |
| 5:00 pm – 5:05 pm | Closing Remarks |
Sunday September 22, 2024
Fairmont Palliser, Calgary, AB
| 7:30 am – 8:30 am | Breakfast |
| 8:30 am – 12:05 pm | Morning Session |
| 8:30 am – 8:35 am | Morning Welcome and Session Introduction |
| 8:35 am – 9:00 am | Optimal Role of Familial Testing in MDS/AML – Who to Test and Novel Mutations – Dr. Lucy Godley |
| 9:00 am – 9:25 am | Optimal Management of CMML – Role of HMA, Venetoclax, Novel Agents – Dr. Mikkael Sekeres |
| 9:25 am – 9:50 am | Transplant Decisions in the Era of the IPSS-M – Speaker TBD |
| 9:50 am – 10:15 am | Optimal management of secondary AML – Speaker TBD |
| 8:30 am – 10:15 am | Nursing Session – Ms. Cindy Murray |
| 8:30 am – 8:35 am | Morning Welcome and Session Introduction |
| 8:35 am – 9:00 am | Lab Testing in MDS and AML – Diagnostic Workup Laboratory Testing |
| 9:00 am – 9:25 am | Prognostic Scores in Myeloid Diseases |
| 9:25 am – 9:50 am | Presentation TBD |
| 9:50 am – 10:15 am | Presentation TBD |
| 10:15 am – 10:35 am | Refreshment Break |
| Morning Session Cont. | |
| 10:35 am – 11:00 am | Maintenance Therapy Post BMT – Dr. Tobias Berg |
| 11:00 am – 11:25 am | Updates in PNH Biology and Management – Dr. Monika Oliver |
| 11:25 am – 11:50 am | VEXAS Syndrome – A New Entity in Hematology With Bone Marrow Failure – Dr. Kareem Jamani |
| 11:50 am – 12:05 pm | Question Period Drs. T. Berg, Dr. M. Oliver, Dr. K. Jamani |
| 12:05 pm – | Closing Remarks |